Stocky turns companies like AbbVie Inc. into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Cautious. ABBV's 75.5 Leadership Alignment (strong insider ownership, disciplined M&A) and reasonable 15.4x forward P/E offer modest appeal, but the company faces a critical structural headwind: Humira patent cliff erosion is ongoing and material. Success hinges entirely on Skyrizi and Rinvoq scaling fast enough to offset revenue decline—a binary execution risk in a mature pharma portfolio.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for AbbVie Inc.:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 49/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates AbbVie Inc. (ABBV) at 49/100 — below the bar Stocky looks for. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Cautious. ABBV's 75.5 Leadership Alignment (strong insider ownership, disciplined M&A) and reasonable 15.4x forward P/E offer modest appeal, but the company faces a critical structural headwind: Humira patent cliff erosion is ongoin
ABBV's current Stocky Verdict is 49/100, placing it in the "Cautious" band. This composite combines a 58/100 Compounder score, 76/100 Leadership, 60/100 Moat rating, and analyst signal.
AbbVie Inc. rates Narrow moat (60/100 Moat Score) — based on 10-year return-on-invested-capital, pricing power, switching costs and network effects. Wide moats compound; Limited moats erode.
AbbVie Inc. scores 76/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
AbbVie Inc.'s Vulnerability Profile scores 33/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to AbbVie Inc..
Sign up free and unlock the full analysis on ABBV — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for ABBV in the app.
